Development of biomarkers to optimize pediatric patient management: what makes children different?
Publication
, Journal Article
Goldman, J; Becker, ML; Jones, B; Clements, M; Leeder, JS
Published in: Biomark Med
December 2011
Despite the frequent utilization of biomarkers in medical practice, there is a relative paucity of information regarding validated pediatric biomarkers. Frequently, biomarkers found to be efficacious in adults are extrapolated to the pediatric clinical setting without considering that the pathogenesis of many diseases is distinctly different in children, and ontogeny directly influences disease evolution and therapeutic response in children. New and innovative approaches are necessary to provide reliable, validated biomarkers that can be used to improve and advance pediatric medical care.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Biomark Med
DOI
EISSN
1752-0371
Publication Date
December 2011
Volume
5
Issue
6
Start / End Page
781 / 794
Location
England
Related Subject Headings
- Reference Values
- Pharmacogenetics
- Pediatrics
- Oncology & Carcinogenesis
- Methotrexate
- Humans
- Genotype
- Folic Acid
- Child
- Biomarkers
Citation
APA
Chicago
ICMJE
MLA
NLM
Goldman, J., Becker, M. L., Jones, B., Clements, M., & Leeder, J. S. (2011). Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark Med, 5(6), 781–794. https://doi.org/10.2217/bmm.11.96
Goldman, Jennifer, Mara L. Becker, Bridgette Jones, Mark Clements, and J Steven Leeder. “Development of biomarkers to optimize pediatric patient management: what makes children different?” Biomark Med 5, no. 6 (December 2011): 781–94. https://doi.org/10.2217/bmm.11.96.
Goldman J, Becker ML, Jones B, Clements M, Leeder JS. Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark Med. 2011 Dec;5(6):781–94.
Goldman, Jennifer, et al. “Development of biomarkers to optimize pediatric patient management: what makes children different?” Biomark Med, vol. 5, no. 6, Dec. 2011, pp. 781–94. Pubmed, doi:10.2217/bmm.11.96.
Goldman J, Becker ML, Jones B, Clements M, Leeder JS. Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark Med. 2011 Dec;5(6):781–794.
Published In
Biomark Med
DOI
EISSN
1752-0371
Publication Date
December 2011
Volume
5
Issue
6
Start / End Page
781 / 794
Location
England
Related Subject Headings
- Reference Values
- Pharmacogenetics
- Pediatrics
- Oncology & Carcinogenesis
- Methotrexate
- Humans
- Genotype
- Folic Acid
- Child
- Biomarkers